- Home
- HOUS vs URGN Comparison
HOUS vs URGN Comparison
Compare HOUS & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOUS
- URGN
- Stock Information
- Founded
- HOUS 2006
- URGN 2004
- Country
- HOUS United States
- URGN United States
- Employees
- HOUS N/A
- URGN N/A
- Industry
- HOUS Real Estate
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- HOUS Finance
- URGN Health Care
- Exchange
- HOUS Nasdaq
- URGN Nasdaq
- Market Cap
- HOUS 445.0M
- URGN 465.9M
- IPO Year
- HOUS 2006
- URGN 2017
- Fundamental
- Price
- HOUS $3.72
- URGN $10.08
- Analyst Decision
- HOUS Sell
- URGN Strong Buy
- Analyst Count
- HOUS 3
- URGN 6
- Target Price
- HOUS $5.33
- URGN $42.25
- AVG Volume (30 Days)
- HOUS 713.4K
- URGN 281.8K
- Earning Date
- HOUS 02-13-2025
- URGN 03-13-2025
- Dividend Yield
- HOUS N/A
- URGN N/A
- EPS Growth
- HOUS N/A
- URGN N/A
- EPS
- HOUS N/A
- URGN N/A
- Revenue
- HOUS $5,692,000,000.00
- URGN $89,363,000.00
- Revenue This Year
- HOUS $8.38
- URGN $12.17
- Revenue Next Year
- HOUS $7.34
- URGN $44.23
- P/E Ratio
- HOUS N/A
- URGN N/A
- Revenue Growth
- HOUS 0.99
- URGN 15.64
- 52 Week Low
- HOUS $2.71
- URGN $9.78
- 52 Week High
- HOUS $6.40
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- HOUS 51.64
- URGN 40.55
- Support Level
- HOUS $3.62
- URGN $9.86
- Resistance Level
- HOUS $4.07
- URGN $11.87
- Average True Range (ATR)
- HOUS 0.25
- URGN 0.50
- MACD
- HOUS 0.03
- URGN -0.04
- Stochastic Oscillator
- HOUS 48.53
- URGN 10.95
About HOUS Anywhere Real Estate Inc.
Anywhere Real Estate Inc operates in residential real estate, focusing on brokerage, relocation, title, settlement businesses, and mortgage and title insurance ventures. It supports approximately 1 million home sale sides annually. Brands include Better Homes and Gardens, CENTURY 21, Coldwell Banker, Corcoran, ERA, and Sotheby's International Realty. Revenue comes mainly from existing home transactions. Operations are segmented into Anywhere Brands (franchises), Anywhere Advisors (owned brokerage), and Anywhere Integrated Services (title and settlement).
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.